Latest Milestone Payments News

Neuren’s partner Acadia secures positive CHMP opinion for DAYBU® in Rett syndrome, paving the way for first EU treatment approval and triggering significant milestone payments for Neuren.

Charger Metals has struck a deal to sell its Bynoe Lithium Project to Core Lithium’s subsidiary for up to $14.75 million, including upfront cash, a resource milestone payment, and a capped royalty. The sale lets Charger focus on its Lake Johnston lithium ambitions.

Platina Resources has completed its acquisition of the Mt Morgans South Project from Genesis Minerals, adding 18 tenements in a prolific gold district and setting the stage for a focused exploration campaign.

Micro-X has cleared a critical design review for its Full Body CT system, unlocking a $1.6 million milestone payment from US government partner ARPA-H and moving into prototype manufacturing.

Micro-X has captured the first human head images using its innovative carbon nanotube cone beam CT technology, marking a major technical milestone as it launches a multi-centre pilot study aimed at stroke diagnosis.

CGN Resources has completed its acquisition of the Desdemona Project, expanding its landholding in the Leonora gold district to a commanding 385 km². The deal positions CGN with multiple high-grade targets and significant greenfield exploration potential along a prolific gold corridor.

Rumble Resources has received the second $5 million milestone payment from Elemental Royalty and satisfied a key condition for its ore toll milling agreement, positioning the Western Queen project for pre-development.

Pacific Resources (ASX: PXR) has advanced its acquisition of the Snowstorm Gold Project in Victoria’s Eastern Goldfields by paying $160,000 to acquire a 50% stake in Mines of Stirling, the project’s owner. Completion of the acquisition, including full ownership, is expected by mid-July.

Acrux has locked in a milestone-based licensing agreement worth up to AUD 5.4 million for Lenzetto®, targeting the Australian menopause therapy market with regulatory and commercial milestones tied to TGA approval and sales performance.

Tetratherix Limited secures $15 million via institutional placement plus a capped $2 million share purchase plan at a 14% discount, aiming to fast-track manufacturing expansion and commercial partnerships.

Acrux has amended its licensing agreement with Gedeon Richter to bring its Estradiol spray Lenzetto® to Australia, unlocking up to AUD 5.4 million in milestone payments and addressing a critical shortage in Menopause Hormone Therapy products.

Neuren Pharmaceuticals reported a 15% rise in 2025 royalties from DAYBUE®, boosted by strong US sales and a new powder formulation launch. The company is progressing its pivotal Phase 3 trial for NNZ-2591 in Phelan-McDermid syndrome and reassessing capital management amid solid cash reserves.